Fresenius SE & Co KGaA (FRA:FRE) PT Set at €65.00 by Deutsche Bank

Deutsche Bank set a €65.00 ($75.58) target price on Fresenius SE & Co KGaA (FRA:FRE) in a research note published on Tuesday, May 7th, Borsen Zeitung reports. The brokerage currently has a buy rating on the stock.

A number of other brokerages also recently issued reports on FRE. Independent Research set a €53.00 ($61.63) target price on Fresenius SE & Co KGaA and gave the stock a neutral rating in a research note on Friday, May 3rd. Berenberg Bank set a €70.95 ($82.50) target price on Fresenius SE & Co KGaA and gave the stock a buy rating in a research note on Thursday, May 2nd. Barclays set a €52.00 ($60.47) price target on Fresenius SE & Co KGaA and gave the stock a neutral rating in a report on Tuesday, April 30th. DZ Bank restated a buy rating on shares of Fresenius SE & Co KGaA in a report on Tuesday, April 2nd. Finally, Morgan Stanley set a €45.00 ($52.33) price target on Fresenius SE & Co KGaA and gave the stock a neutral rating in a report on Tuesday, April 16th. Ten equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The stock presently has a consensus rating of Buy and an average target price of €59.55 ($69.24).

FRE traded down €1.41 ($1.64) on Tuesday, hitting €46.34 ($53.88). 1,784,179 shares of the company traded hands. Fresenius SE & Co KGaA has a 12-month low of €60.16 ($69.95) and a 12-month high of €80.00 ($93.02).

About Fresenius SE & Co KGaA

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

See Also: Bollinger Bands

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply